Modality
Gene Therapy
MOA
C5i
Target
RET
Pathway
NF-κB
OCD
Development Pipeline
Preclinical
~May 2023
→ ~Aug 2024
Phase 1
Nov 2024
→ Feb 2030
Phase 1Current
NCT04357342
2,540 pts·OCD
2024-11→2028-05·Recruiting
NCT06851408
902 pts·OCD
2025-09→2030-02·Terminated
3,442 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-05-262.2y awayInterim· OCD
2030-02-053.9y awayInterim· OCD
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1
Recruit…
P1
Termina…
Catalysts
Interim
2028-05-26 · 2.2y away
OCD
Interim
2030-02-05 · 3.9y away
OCD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04357342 | Phase 1 | OCD | Recruiting | 2540 | EASI-75 |
| NCT06851408 | Phase 1 | OCD | Terminated | 902 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Fixabrutinib | Verve | Phase 1 | RET |